This isn't just a stock pick; it's a strategic bet on the discovery of a new generation of medicines for diseases currently deemed incurable. 
RXRX (Recursion Pharmaceuticals) is at the forefront of the AI-biotech revolution, moving away from traditional trial-and-error towards a high-speed, data-driven approach. While the company is currently burning cash and fails standard ROE/Margin filters, its 33.3% revenue growth and massive $660M cash reserve prove that the industry giants (Nvidia, Roche) are taking this seriously. We are looking at a platform that could fundamentally change how we treat humanity's toughest illnesses. At nearly 60% below its DCF fair value, this is a high-risk/high-reward play for those who believe that AI will be the one to finally unlock the cures we've been waiting for. Patience is key as clinical milestones approach.
RXRX (Recursion Pharmaceuticals) is at the forefront of the AI-biotech revolution, moving away from traditional trial-and-error towards a high-speed, data-driven approach. While the company is currently burning cash and fails standard ROE/Margin filters, its 33.3% revenue growth and massive $660M cash reserve prove that the industry giants (Nvidia, Roche) are taking this seriously. We are looking at a platform that could fundamentally change how we treat humanity's toughest illnesses. At nearly 60% below its DCF fair value, this is a high-risk/high-reward play for those who believe that AI will be the one to finally unlock the cures we've been waiting for. Patience is key as clinical milestones approach.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.